Find Patient Assistance
Your OCREVUS Patient Navigator can help identify assistance options for eligible patients, or you can use the Patient Assistance Tool below.
To use this tool, answer a few simple questions to find out which
patient assistance option might be right for your patient.
-
Is your patient insured?
-
Does the patient's insurance cover his or her Genentech medicine?
-
Does your patient have commercial insurance?
What does this mean? -
Has your patient already been referred to the OCREVUS Co-pay Program and is either ineligible or no longer receiving assistance?
-
Has your patient already been referred to an independent co-pay assistance foundation and is either ineligible or no longer receiving assistance?
-
Is the patient using OCREVUS for an FDA-approved indication?
Your Patient Might Qualify for the OCREVUS Co-pay Program
If eligible commercially insured patients need assistance with their out-of-pocket costs, your OCREVUS Patient Navigator can help them enroll in the OCREVUS Co-pay Program.*
*In order to be eligible for the OCREVUS Co-pay Program, the patient must have commercial insurance, must not have Medicare, Medicaid or other government insurance, and must meet other eligibility criteria. They also must agree to the rules set forth in the terms and conditions for the program. Please visit OCREVUSCopay.com/HCP for the full list of terms and conditions.
Your Patient Might Qualify for a Referral to an Independent Co-pay Assistance Foundation
If eligible publicly or commercially insured patients have difficulty paying for their co-pay, co-insurance or other out-of-pocket (OOP) costs, your OCREVUS Patient Navigator can refer them to an independent co-pay assistance foundation supporting their disease state.*
*Genentech does not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from OCREVUS Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech’s endorsement or financial support. There may be other foundations to support the patient's disease state.
Your Patient Might Qualify for a Referral to the Genentech Patient Foundation
The Genentech Patient Foundation provides free Genentech medicine to people who don't have insurance coverage or who have financial concerns and to people who meet certain income criteria.*
*To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the OCREVUS Co-pay Program and support from independent co-pay assistance foundations) and must meet financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.
Patient Assistance Options
The OCREVUS Co-pay Program
Your Patient Navigator can help eligible commercially insured patients enroll in the OCREVUS Co-pay Program for help with the out-of-pocket costs associated with their Genentech medicine.*
Referrals to Independent Co-pay Assistance Foundations
For eligible patients with commercial or public health insurance, your OCREVUS Patient Navigator offers referrals to independent co-pay assistance foundations.†
Referrals to the Genentech Patient Foundation
The Genentech Patient Foundation provides free Genentech medicine to people who don't have insurance coverage or who have financial concerns and to people who meet certain income criteria.‡
*In order to be eligible for the OCREVUS Co-pay Program, the patient must have commercial insurance, must not have Medicare, Medicaid or other government insurance, and must meet other eligibility criteria. They also must agree to the rules set forth in the terms and conditions for the program. Please visit OCREVUSCopay.com/HCP for the full list of terms and conditions.
†Genentech does not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from OCREVUS Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech’s endorsement or financial support. There may be other foundations to support the patient's disease state.
‡To be eligible for free Genentech medicine from the Genentech
Patient Foundation, insured patients who have coverage for their
medicine must have exhausted all other forms of patient assistance
(including the OCREVUS Co-pay Program and support from independent
co-pay assistance foundations) and must meet financial criteria.
Uninsured patients and insured patients without coverage for their
medicine must meet different financial criteria.
PAN=Patient Authorization and Notice of Request for Transmission of Health Information to Genentech Access Solutions and Genentech® Access to Care Foundation.
SMN=Statement of Medical Necessity.
Important Safety Information & Indication
Indications
OCREVUS is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis.
Contraindications
OCREVUS is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening infusion reaction to OCREVUS.
Warnings and Precautions
Infusion Reactions:
Management recommendations for infusion reactions depend on the type and severity of the reaction. Permanently discontinue OCREVUS if a life-threatening or disabling infusion reaction occurs.
Infections:
Delay OCREVUS administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with OCREVUS and after discontinuation, until B-cell repletion.
Malignancies:
An increased risk of malignancy, including breast cancer, may exist with OCREVUS.
Most Common Adverse Reactions
RMS: The most common adverse reactions in RMS trials (incidence ≥10% and >REBIF): upper respiratory tract infections and infusion reactions.
PPMS: The most common adverse reactions (≥10% and >placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections.
For additional safety information, please see the full Prescribing Information and Medication Guide.